---
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265400072.md"
description: "The Nasdaq Biotechnology Index rose by more than 2.9%. Among them, Theravance BioPharma rose by 22.55%, Edgewise Therapeutics rose by 17.51%, uniQure NV rose by 17.48%, and Autolus Therapeutics rose by 14.39%. In contrast, Pyxis Oncology fell by 4.19%, Humacyte fell by 5.19%, and Olema fell by 5.86%"
datetime: "2025-11-11T21:43:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265400072.md)
  - [en](https://longbridge.com/en/news/265400072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265400072.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265400072.md) | [English](https://longbridge.com/en/news/265400072.md)


# 

The Nasdaq Biotechnology Index closed up over 2.9%, with component stock Theravance BioPharma rising 22.55%, Edgewise Therapeutics up 17.51%, uniQure NV up 17.48%, and Autolus Therapeutics up 14.39% in fourth place. Pyxis Oncology, on the other hand, fell 4.19%, ranking third from the bottom, followed by Humacyte down 5.19% and Olema down 5.86%

### 相關股票

- [Autolus Therapeutics (AUTL.US)](https://longbridge.com/zh-HK/quote/AUTL.US.md)
- [Uniqure (QURE.US)](https://longbridge.com/zh-HK/quote/QURE.US.md)
- [Theravance BioPharma (TBPH.US)](https://longbridge.com/zh-HK/quote/TBPH.US.md)
- [Edgewise Therapeutics (EWTX.US)](https://longbridge.com/zh-HK/quote/EWTX.US.md)

## 相關資訊與研究

- [09:00 ETQURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm](https://longbridge.com/zh-HK/news/281192427.md)
- [Pyxis Oncology Reports Q4 Results, Advances MICVO Program](https://longbridge.com/zh-HK/news/280152320.md)
- [13:00 ETuniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline](https://longbridge.com/zh-HK/news/281059340.md)
- [08:19 ETQURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026](https://longbridge.com/zh-HK/news/280909742.md)
- [16:37 ETQURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data](https://longbridge.com/zh-HK/news/280685519.md)